CLINICAL TRIALS PROFILE FOR OXTELLAR XR
✉ Email this page to a colleague
All Clinical Trials for OXTELLAR XR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00772603 ↗ | Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures | Completed | Parexel | Phase 3 | 2008-11-01 | Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures |
| NCT00772603 ↗ | Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures | Completed | Supernus Pharmaceuticals, Inc. | Phase 3 | 2008-11-01 | Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures |
| NCT03374709 ↗ | Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia | Withdrawn | University of Colorado, Denver | Phase 4 | 2018-12-14 | To evaluate the affect Oxtellar XR (Extended Release) has on neurology patients with trigeminal neuralgia (TN), and if it impacts their quality of life. |
| NCT03567681 ↗ | Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression | Unknown status | Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen Hospital | Phase 4 | 2018-06-13 | Consenting subjects with Bipolar depression will remain under the care of their local (psychiatric) care provider and be randomized to a six week course of one of two forms of oxcarbazepine (extended release or immediate release. Study outcomes will be assessed based on outcome measures administered to the subject at home by a computer simulated rater. Local care providers will receive "pre-assessment" reports ahead of each clinical visit, rate the Clinical Global Impression for Severity, and evaluate adverse effects. The primary outcome variable is "treatment effectiveness" operationally defined as the response rate X the completion rate. |
| NCT03567681 ↗ | Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression | Unknown status | Collaborative Care Initiative, LLC | Phase 4 | 2018-06-13 | Consenting subjects with Bipolar depression will remain under the care of their local (psychiatric) care provider and be randomized to a six week course of one of two forms of oxcarbazepine (extended release or immediate release. Study outcomes will be assessed based on outcome measures administered to the subject at home by a computer simulated rater. Local care providers will receive "pre-assessment" reports ahead of each clinical visit, rate the Clinical Global Impression for Severity, and evaluate adverse effects. The primary outcome variable is "treatment effectiveness" operationally defined as the response rate X the completion rate. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OXTELLAR XR
Condition Name
Clinical Trial Locations for OXTELLAR XR
Trials by Country
Clinical Trial Progress for OXTELLAR XR
Clinical Trial Phase
Clinical Trial Sponsors for OXTELLAR XR
Sponsor Name
